Catalyst Founder and CEO, Nancy Myers, moderated a panel on Thursday, September 24th, 2020 at the (virtual) ASGCT Policy Summit. The panel was on “Overcoming Regulatory Challenges in Gene Therapy Development.”

The panelists and their presentation topics are:

  • Anne-Virginie Eggimann, Senior Vice-President, Regulatory Science, bluebird bio
    “Regulatory considerations to improve gene therapy development throughout life cycle”
  • Ying Huang, Ph.D., Pharmacologist, Pharmacology/Toxicology Branch, FDA
    “Selecting appropriate animal models for clinical success”
  • Becky Schweighardt, Ph.D., Senior Director, Immunogenicity Assessment, BioMarin
    “Addressing immunogenicity in clinical trials”

For more information and to register, click HERE.